도파민 수용체3 D

Dopamine receptor D3
DRD3
3PBL (D3).png
사용 가능한 구조물
PDB직교 검색: PDBe RCSB
식별자
별칭DRD3, D3DR, ETM1, FET1, 도파민 수용체 D3
외부 IDOMIM: 126451 MGI: 94925 HomoloGene: 623 GeneCard: DRD3
직교체
종인간마우스
엔트레스

1814

13490

앙상블

ENSG00000151577

ENSMUSG00000022705

유니프로트

P35462

P30728

RefSeq(mRNA)

NM_007877

RefSeq(단백질)

NP_000787
NP_001269492
NP_001277738
NP_387512

NP_031903

위치(UCSC)Chr 3: 114.13 – 114.2MbCr 16: 43.75 – 43.82Mb
PubMed 검색[3][4]
위키다타
인간 보기/편집마우스 보기/편집

도파민 수용체 D는3 인간에게 있어서 DRD3 유전자에 의해 암호화된 단백질이다.[5][6]

이 유전자는 도파민 수용체의 D 아형을3 인코딩한다. D3 하위타입은 억제 G단백질을 통해 아데닐 사이클라아제를 억제한다. 이 수용체는 뇌에서 혈전학적으로 더 오래된 부위로 표현되며, 이 수용체가 인지 및 감정 기능에 역할을 한다는 것을 암시한다.[citation needed] 조현병, 약물중독, 파킨슨병을 치료하는 약의 대상이다.[7] 이 유전자의 대체적인 스플라이싱은 다른 등소형태를 부호화할 수 있는 다중 대본 변형을 야기한다. 비록 일부 변종들은 난센스 매개 부패(NMD)[6]에 노출될 수 있다.

함수

7-OH-DPAT, 프라미펙솔, 로티고틴과 같은 D3 작용제는 설치류 우울증 모델에서 항우울제 효과를 나타낸다.[8][9]

동물학

D원인은3 조현병 등 신경정신과 질환의 센서리모터 게이팅 결손을 재점검하는 이종교배 대책인 '스타틀 사전 억제(PPI)'를 교란하는 것으로 나타났다.[10][11][12] 이와는 대조적으로, D3 선호 길항제들은 랫드의 PPI 측정에서 항정신병 약물 같은 프로파일을 가지고 있다.[13]

리간즈

고민자

부분작용제

반목자

상호작용

도파민 수용체 D는3 CLIC6[30] 및 EPB41L1과 상호작용하는 것으로 나타났다.[31]

참고 항목

참조

  1. ^ a b c GRCh38: 앙상블 릴리스 89: ENSG00000151577 - 앙상블, 2017년 5월
  2. ^ a b c GRCm38: 앙상블 릴리스 89: ENSMUSG000022705 - 앙상블, 2017년 5월
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Le Coniat M, Sokoloff P, Hillion J, Martres MP, Giros B, Pilon C, Schwartz JC, Berger R (September 1991). "Chromosomal localization of the human D3 dopamine receptor gene". Human Genetics. 87 (5): 618–20. doi:10.1007/bf00209024. PMID 1916765. S2CID 28411786.
  6. ^ a b "Entrez Gene: DRD3 dopamine receptor D3".
  7. ^ Joyce JN, Millan MJ (February 2007). "Dopamine D3 receptor agonists for protection and repair in Parkinson's disease". Current Opinion in Pharmacology. 7 (1): 100–5. doi:10.1016/j.coph.2006.11.004. PMID 17174156.
  8. ^ Breuer ME, Groenink L, Oosting RS, Buerger E, Korte M, Ferger B, Olivier B (August 2009). "Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats". European Journal of Pharmacology. 616 (1–3): 134–40. doi:10.1016/j.ejphar.2009.06.029. PMID 19549514.
  9. ^ Bertaina-Anglade V, La Rochelle CD, Scheller DK (October 2006). "Antidepressant properties of rotigotine in experimental models of depression". European Journal of Pharmacology. 548 (1–3): 106–14. doi:10.1016/j.ejphar.2006.07.022. PMID 16959244.
  10. ^ Weber M, Chang WL, Breier M, Ko D, Swerdlow NR (December 2008). "Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation". Behavioural Pharmacology. 19 (8): 786–95. doi:10.1097/FBP.0b013e32831c3b2b. PMC 3255557. PMID 19020413.
  11. ^ Chang WL, Swerdlow NR, Breier MR, Thangaraj N, Weber M (June 2010). "Parametric approaches towards understanding the effects of the preferential D3 receptor agonist pramipexole on prepulse inhibition in rats". Pharmacology Biochemistry and Behavior. 95 (4): 473–8. doi:10.1016/j.pbb.2010.04.001. PMC 2889248. PMID 20385162.
  12. ^ Chang WL, Weber M, Breier MR, Saint Marie RL, Hines SR, Swerdlow NR (February 2012). "Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats". Brain Research. 1437: 69–76. doi:10.1016/j.brainres.2011.12.007. PMC 3268831. PMID 22227455.
  13. ^ Weber M, Chang WL, Durbin JP, Park PE, Luedtke RR, Mach RH, Swerdlow NR (August 2009). "Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44". Pharmacology Biochemistry and Behavior. 93 (2): 141–7. doi:10.1016/j.pbb.2009.04.022. PMC 2720754. PMID 19426754.
  14. ^ Leopoldo M, Lacivita E, Colabufo NA, Berardi F, Perrone R (February 2006). "Synthesis and binding profile of constrained analogues of N-[4-(4-arylpiperazin-1-yl)butyl]-3-methoxybenzamides, a class of potent dopamine D3 receptor ligands". The Journal of Pharmacy and Pharmacology. 58 (2): 209–18. doi:10.1211/jpp.58.2.0008. PMID 16451749. S2CID 42910160.
  15. ^ Biswas S, Zhang S, Fernandez F, Ghosh B, Zhen J, Kuzhikandathil E, Reith ME, Dutta AK (January 2008). "Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action". Journal of Medicinal Chemistry. 51 (1): 101–17. doi:10.1021/jm070860r. PMID 18072730.
  16. ^ Perachon, Sylvie; Schwartz, Jean-Charles; Sokoloff, Pierre (February 1999). "Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors". European Journal of Pharmacology. 366 (2–3): 293–300. doi:10.1016/S0014-2999(98)00896-6. PMID 10082211.
  17. ^ Chen J, Collins GT, Levant B, Woods J, Deschamps JR, Wang S (August 2011). "CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist". ACS Medicinal Chemistry Letters. 2 (8): 620–625. doi:10.1021/ml200100t. PMC 3224040. PMID 22125662.
  18. ^ Peglion JL, Poitevin C, Mannoury La Cour C, Dupuis D, Millan MJ (April 2009). "Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: improvements of affinity and selectivity for D3 versus D2 receptors". Bioorganic & Medicinal Chemistry Letters. 19 (8): 2133–8. doi:10.1016/j.bmcl.2009.03.015. PMID 19324548.
  19. ^ Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, Cook AS, Nichols CL, Phipps J, Sanderson VG, Verrier H, Wong S (December 2007). "Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route". Bioorganic & Medicinal Chemistry Letters. 17 (24): 6691–6. doi:10.1016/j.bmcl.2007.10.059. PMID 17976986.
  20. ^ Collins GT, Butler P, Wayman C, Ratcliffe S, Gupta P, Oberhofer G, Caine SB (June 2012). "Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats". Behavioural Pharmacology. 23 (3): 280–91. doi:10.1097/FBP.0b013e3283536d21. PMC 3365486. PMID 22470105.
  21. ^ Cagnotto A, Parotti L, Mennini T (October 1996). "In vitro affinity of piribedil for dopamine D3 receptor subtypes, an autoradiographic study". European Journal of Pharmacology. 313 (1–2): 63–7. doi:10.1016/0014-2999(96)00503-1. PMID 8905329.
  22. ^ Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR, Heidbreder C, Gaál J, Gardner EL (March 2008). "The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats". Psychopharmacology. 196 (4): 533–42. doi:10.1007/s00213-007-0986-6. PMC 3713235. PMID 17985117.
  23. ^ Chen J, Collins GT, Zhang J, Yang CY, Levant B, Woods J, Wang S (October 2008). "Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile". Journal of Medicinal Chemistry. 51 (19): 5905–8. doi:10.1021/jm800471h. PMC 2662387. PMID 18785726.
  24. ^ Dörfler M, Tschammer N, Hamperl K, Hübner H, Gmeiner P (November 2008). "Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies". Journal of Medicinal Chemistry. 51 (21): 6829–38. doi:10.1021/jm800895v. PMID 18834111.
  25. ^ a b Bettinetti L, Schlotter K, Hübner H, Gmeiner P (October 2002). "Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists". Journal of Medicinal Chemistry. 45 (21): 4594–7. doi:10.1021/jm025558r. PMID 12361386.
  26. ^ Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH (February 2005). "Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor". Journal of Medicinal Chemistry. 48 (3): 839–48. doi:10.1021/jm049465g. PMID 15689168.
  27. ^ Mason CW, Hassan HE, Kim KP, Cao J, Eddington ND, Newman AH, Voulalas PJ (June 2010). "Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse". The Journal of Pharmacology and Experimental Therapeutics. 333 (3): 854–64. doi:10.1124/jpet.109.165084. PMC 2879935. PMID 20228156.
  28. ^ Newman AH, Grundt P, Cyriac G, Deschamps JR, Taylor M, Kumar R, Ho D, Luedtke RR (April 2009). "N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists". Journal of Medicinal Chemistry. 52 (8): 2559–70. doi:10.1021/jm900095y. PMC 2760932. PMID 19331412.
  29. ^ Xi ZX, Gardner EL (2007). "Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction". CNS Drug Reviews. 13 (2): 240–59. doi:10.1111/j.1527-3458.2007.00013.x. PMC 3771110. PMID 17627675.
  30. ^ Griffon N, Jeanneteau F, Prieur F, Diaz J, Sokoloff P (September 2003). "CLIC6, a member of the intracellular chloride channel family, interacts with dopamine D(2)-like receptors". Brain Research. Molecular Brain Research. 117 (1): 47–57. doi:10.1016/S0169-328X(03)00283-3. PMID 14499480.
  31. ^ Binda AV, Kabbani N, Lin R, Levenson R (September 2002). "D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N". Molecular Pharmacology. 62 (3): 507–13. doi:10.1124/mol.62.3.507. PMID 12181426.

추가 읽기

외부 링크

이 기사는 공공영역에 있는 미국 국립 의학 도서관의 텍스트를 통합하고 있다.